Neuroblastoma

Neuroblastoma is cancer that arises in immature nerve cells and affects mostly infants and children.

What is Neuroblastoma?

Neuroblastoma is a rare childhood cancer that develops from immature nerve cells called neuroblasts.

Latest Neuroblastoma News and Research

New study explains why neuroblastoma returns years later

Cancer is the leading cause of disease-related death in childhood. This is in part due to cancer-associated genes called oncogenes that can be found far from chromosomes in cell nuclei on ring-shaped DNA inside tumor cells.

14 Aug 2025

Using machine learning framework to identify prognostic biomarkers in neuroblastoma

Neuroblastoma is the most common solid tumor in infants and accounts for nearly 15% of all pediatric cancer-related deaths.

11 Aug 2025

Lauric acid could be a key cancer-fighting compound in coconut oil

Virgin coconut oil and lauric acid show promise in inhibiting cancer cell growth and mitigating chemotherapy toxicity, paving the way for future therapies.

11 Aug 2025

Study reveals critical role of the extracellular matrix in neuroblastoma progression

A groundbreaking study led by Children's Hospital Los Angeles has found a novel mechanism behind neuroblastoma progression: the shape and structure of the extracellular matrix.

16 Jul 2025

Scientists reveal how chemotherapy causes genetic damage in healthy blood

For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.

2 Jul 2025

Uncommitted cells offer clues to neuroblastoma regression

Neuroblastoma is a cancer that affects the sympathetic nervous system of children. It is unusual among cancers because it shows a range of outcomes: from aggressive, potentially fatal progression to a unique phenomenon where the tumor spontaneously regresses even without treatment.

25 Jun 2025

Targeting ST6Gal-I shows promise in reducing Alzheimer’s disease pathology

A recent study published in Engineering has provided novel insights into the involvement of α2,6-sialylation in Alzheimer's disease (AD), revealing that the ablation of α2,6-sialyltransferase-I (ST6Gal-I), an enzyme responsible for α2,6-sialylation, can downregulate BACE1 expression and suppress the production of amyloid-β42 (Aβ42) plaques, which are hallmarks of AD.

20 Jun 2025

Researchers identify a new treatment strategy for neuroblastoma

Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an aggressive form of childhood cancer.

16 Jun 2025

FOXR2 activation found in multiple pediatric brain tumor types

Physicians classify brain tumors and determine treatment options, in part, by the genes they express. According to World Health Organization standards, the abnormal activation of oncogene FOXR2 only occurs in central nervous system (CNS) neuroblastoma, but that may not be true.

16 Apr 2025

Blood test detects Parkinson’s years before symptoms appear using RNA markers

A new study identifies a blood-based biomarker that detects pre-symptomatic Parkinson’s disease by measuring the ratio of specific nuclear and mitochondrial transfer RNA fragments. The test outperforms standard clinical tools and may also reflect disease mechanisms related to impaired protein synthesis.

14 Apr 2025

Researchers explore drug repurposing strategy for Parkinson's disease

Despite significant advances in Parkinson's disease (PD) treatment, it remains incurable, with limited therapeutic options.

10 Apr 2025

Dynamic BH3 profiling offers personalized lung cancer therapies

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication.

9 Apr 2025

Neuropeptide Y identified as key driver of pancreatic cancer spread

Researchers at the Garvan Institute of Medical Research have uncovered how pancreatic cancer hijacks a crucial metabolism 'switch' to help it spread, revealing a potential new treatment strategy for this highly aggressive disease.

17 Mar 2025

St. Jude scientists discover how retinoic acid selectively kills metastatic neuroblastoma cells

Neuroblastoma is a solid tumor that occurs in children. When high-risk, the disease has a poor prognosis. Decades ago, adding the drug retinoic acid to neuroblastoma treatment increased survival by 10-15%.

2 Mar 2025

Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatment

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children with neuroblastoma, with one patient remaining cancer-free for over 18 years.

17 Feb 2025

Targeting MYCN and MDM2 offers new hope for cancer therapy

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

29 Jan 2025

Metronomic chemotherapy offers hope for children with neuroblastoma

Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced stage, often with metastatic disease.

23 Jan 2025

New insights into rare liver cancer as clinical trial for treatment begins

Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC) mounts a ferocious attack against an unlucky few-in this case, children, adolescents, and young adults.

17 Jan 2025

Study provides new insights into the genetic underpinnings of pediatric cancers

Largescale changes in the genome inherited from parents are significant risk factors for pediatric solid tumors, such as Ewing sarcoma, neuroblastoma, and osteosarcoma, according to a new study.

2 Jan 2025

Ketone body β-hydroxybutyrate restores protein balance and targets Alzheimer’s-linked aggregates

Scientists identify β-hydroxybutyrate as a key regulator of protein solubility, offering a novel pathway to combat neurodegeneration in aging and Alzheimer’s disease.

4 Dec 2024